juicyleft.blogg.se - Anti human fgfr3 antibody cross reactivity

Anti human fgfr3 antibody cross reactivity pdf#

108010081267 Type 3 Fibroblast Growth Factor Receptor Proteins 0.000 claims description 162.

230000004913 activation Effects 0.000 title claims description 75.

108090001123 antibodies Proteins 0.000 title claims description 141.

102000004965 antibodies Human genes 0.000 title claims description 141.

Application filed by Fibron Ltd filed Critical Fibron Ltd Publication of EP1423428A2 publication Critical patent/EP1423428A2/en Publication of EP1423428A4 publication Critical patent/EP1423428A4/en Publication of EP1423428B1 publication Critical patent/EP1423428B1/en Application granted granted Critical Publication of EP1423428B2 publication Critical patent/EP1423428B2/en Anticipated expiration legal-status Critical Status Expired - Lifetime legal-status Critical Current Links Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Family has litigation Priority claimed from US29918701P external-priority First worldwide family litigation filed litigation Critical (B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License. Original Assignee Fibron Ltd Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) ( en Inventor Avner Yayon Eran Rom Elisabeth Thomassen-Wolf Eric Borges Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Expired - Lifetime Application number EP02741132A Other languages German ( de)

Anti human fgfr3 antibody cross reactivity pdf#

Google Patents Antibodies that block fgfr3 activation, methods of screening for and uses thereofĭownload PDF Info Publication number EP1423428B1 EP1423428B1 EP02741132A EP02741132A EP1423428B1 EP 1423428 B1 EP1423428 B1 EP 1423428B1 EP 02741132 A EP02741132 A EP 02741132A EP 02741132 A EP02741132 A EP 02741132A EP 1423428 B1 EP1423428 B1 EP 1423428B1 Authority EP European Patent Office Prior art keywords seq fgfr3 region antigen binding antibody Prior art date Legal status (The legal status is an assumption and is not a legal conclusion.

Google Patents EP1423428B1 - Antibodies that block fgfr3 activation, methods of screening for and uses thereof

Not for resale without express authorization.EP1423428B1 - Antibodies that block fgfr3 activation, methods of screening for and uses thereof Three alternatively spliced transcript variants that encode different protein isoforms have been described.įor Research Use Only. Mutations in this gene lead to craniosynostosis and multiple types of skeletal dysplasia. This particular family member binds acidic and basic fibroblast growth hormone and plays a role in bone development and maintenance. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. A full-length representative protein would consist of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. FGFR family members differ from one another in their ligand affinities and tissue distribution. This gene encodes a member of the fibroblast growth factor receptor (FGFR) family, with its amino acid sequence being highly conserved between members and among divergent species.